Annovis Bio Appoints Hui Liu as Director of Biostatistics
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative disorders, has appointed Hui Liu as Director of Biostatistics. This strategic hire comes as the company advances its pivotal Phase 3 Alzheimer's disease trial.
Ms. Liu brings over 19 years of experience in clinical trial statistics, specializing in:
- Design and analysis of all clinical trial phases
- Statistical methodology expertise
- Development of statistical analysis plans
- Management of high-performing teams
According to Dr. Cheng Fang, Senior VP of Research and Development, Liu's appointment strengthens the company's scientific excellence and will support data integrity for regulatory submissions. The new Director expressed enthusiasm about joining Annovis's team and contributing to their clinical trials' quality evidence generation.
Annovis Bio (NYSE: ANVS), un'azienda di piattaforma farmaceutica in fase avanzata focalizzata sui disturbi neurodegenerativi, ha nominato Hui Liu come Direttrice di Biostatistica. Questa nomina strategica avviene mentre l'azienda procede con il suo cruciale studio di Fase 3 sulla malattia di Alzheimer.
La signora Liu vanta oltre 19 anni di esperienza nelle statistiche per studi clinici, con specializzazione in:
- Progettazione e analisi di tutte le fasi degli studi clinici
- Competenza nelle metodologie statistiche
- Sviluppo di piani di analisi statistica
- Gestione di team ad alte prestazioni
Secondo il dottor Cheng Fang, Vicepresidente Senior di Ricerca e Sviluppo, la nomina di Liu rafforza l'eccellenza scientifica dell'azienda e supporterà l'integrità dei dati per le presentazioni regolatorie. La nuova Direttrice ha espresso entusiasmo per l'ingresso nel team di Annovis e per il contributo alla generazione di prove di qualità negli studi clinici.
Annovis Bio (NYSE: ANVS), una empresa farmacéutica en etapa avanzada centrada en trastornos neurodegenerativos, ha nombrado a Hui Liu como Directora de Bioestadística. Esta contratación estratégica se produce mientras la compañía avanza en su crucial ensayo clínico de Fase 3 para la enfermedad de Alzheimer.
La Sra. Liu aporta más de 19 años de experiencia en estadísticas de ensayos clínicos, especializada en:
- Diseño y análisis de todas las fases de ensayos clínicos
- Experiencia en metodologías estadísticas
- Desarrollo de planes de análisis estadístico
- Gestión de equipos de alto rendimiento
Según el Dr. Cheng Fang, Vicepresidente Senior de Investigación y Desarrollo, el nombramiento de Liu fortalece la excelencia científica de la empresa y apoyará la integridad de los datos para las presentaciones regulatorias. La nueva Directora expresó entusiasmo por unirse al equipo de Annovis y contribuir a la generación de evidencia de calidad en los ensayos clínicos.
Annovis Bio (NYSE: ANVS)는 신경퇴행성 질환에 중점을 둔 후기 임상 단계의 신약 플랫폼 회사로, Hui Liu를 생물통계학 이사로 임명했습니다. 이 전략적 채용은 회사가 중요한 알츠하이머병 3상 임상시험을 진행하는 가운데 이루어졌습니다.
류 이사는 임상시험 통계 분야에서 19년 이상의 경력을 보유하고 있으며, 전문 분야는 다음과 같습니다:
- 모든 임상시험 단계의 설계 및 분석
- 통계 방법론 전문성
- 통계 분석 계획 개발
- 고성능 팀 관리
연구개발 수석 부사장인 Cheng Fang 박사는 류 이사의 임명이 회사의 과학적 우수성을 강화하고 규제 제출을 위한 데이터 무결성을 지원할 것이라고 밝혔습니다. 신임 이사는 Annovis 팀에 합류하여 임상시험의 질 높은 증거 생성에 기여하게 되어 기쁘다고 전했습니다.
Annovis Bio (NYSE : ANVS), une entreprise de plateforme pharmaceutique en phase clinique avancée spécialisée dans les troubles neurodégénératifs, a nommé Hui Liu au poste de Directrice de la Biostatistique. Ce recrutement stratégique intervient alors que la société fait progresser son essai pivot de Phase 3 sur la maladie d'Alzheimer.
Mme Liu apporte plus de 19 ans d'expérience en statistiques d'essais cliniques, avec une spécialisation dans :
- La conception et l'analyse de toutes les phases des essais cliniques
- L'expertise en méthodologies statistiques
- Le développement de plans d'analyse statistique
- La gestion d'équipes performantes
Selon le Dr Cheng Fang, vice-président principal de la Recherche et Développement, la nomination de Mme Liu renforce l'excellence scientifique de l'entreprise et soutiendra l'intégrité des données pour les soumissions réglementaires. La nouvelle Directrice a exprimé son enthousiasme à rejoindre l'équipe d'Annovis et à contribuer à la production de preuves de qualité dans les essais cliniques.
Annovis Bio (NYSE: ANVS), ein Pharmaunternehmen in der späten klinischen Entwicklungsphase mit Schwerpunkt auf neurodegenerativen Erkrankungen, hat Hui Liu als Direktorin für Biostatistik ernannt. Diese strategische Einstellung erfolgt, während das Unternehmen seine entscheidende Phase-3-Studie zur Alzheimer-Krankheit vorantreibt.
Frau Liu bringt über 19 Jahre Erfahrung in der Statistik klinischer Studien mit, spezialisiert auf:
- Design und Analyse aller klinischen Studienphasen
- Fachwissen in statistischen Methoden
- Entwicklung statistischer Analysepläne
- Leitung leistungsstarker Teams
Dr. Cheng Fang, Senior Vice President für Forschung und Entwicklung, erklärt, dass die Ernennung von Liu die wissenschaftliche Exzellenz des Unternehmens stärkt und die Datenintegrität für behördliche Einreichungen unterstützt. Die neue Direktorin äußerte ihre Begeisterung, dem Annovis-Team beizutreten und zur hochwertigen Evidenzgenerierung in klinischen Studien beizutragen.
- Strengthens clinical data analysis capabilities with experienced biostatistics hire for Phase 3 AD trial
- New director brings 19 years of experience in clinical trials and regulatory submissions
- Strategic hire aligns with late-stage development of Alzheimer's and Parkinson's treatments
- None.
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics.
“Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence,” said Cheng Fang, Ph.D., Senior Vice President, Research and Development. “Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move toward our goals.”
Ms. Liu has over 19 years of experience in design, analysis, and reporting all phases of clinical trials across a broad range of therapeutic areas. She brings deep expertise in statistical methodology, including authoring statistical analysis plans, developing programming specifications, and interpreting complex data to support regulatory submissions. In addition to her technical strengths, Ms. Liu has led high-performing teams, managed large accounts, and driven strategic initiatives with a focus on quality, efficiency, and collaboration.
"I’m excited to join Annovis and honored to work with a passionate and driven team,” commented Ms. Liu. “I look forward to applying my statistical expertise to further enhance the integrity of the company’s clinical trials and to help generate high-quality evidence that will support scientific advancement and regulatory success.”
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
What role will Hui Liu play at Annovis Bio (ANVS) in 2025?
How does Hui Liu's appointment impact ANVS Phase 3 Alzheimer's trial?
What experience does Hui Liu bring to Annovis Bio (ANVS)?
Which neurodegenerative diseases is Annovis Bio (ANVS) targeting?
What stage is Annovis Bio (ANVS) in their drug development process?
